Partner
New York Office | tom.bird@torreya.com | 212.257.5806
Tom Bird is a Partner at Torreya. Tom has more than 40 years of business development, transaction, and operating experience with global Life Science companies. An expert in branded pharmaceuticals, life science tools, generics products, and pharma manufacturing, he has worked on dozens of life-sciences transactions.
Before joining Torreya in 2007, Tom was Vice President of Corporate Development at Cambrex, where he played a key role in the divestiture of manufacturing plants in Ireland and Belgium, and the sale of Cambrex Bio-Subsidiaries to Lonza. Prior to that, as President of Cambrex’s Biosciences Group, Tom built the BioWhittaker cell biology division into a powerhouse supply business through a combination of organic growth and acquisitions. Tom initially joined Cambrex as President of the Nepera Chemical business. Earlier in his career, he was President of Cuno, a filtration and separation company, and President of the Sherwin Williams Consumer Division.
Tom holds a B.A. from Muhlenberg College.
![]() |
Sale of Noden to |
![]() |
Up to $52.83 Million
September 2020
|
![]() |
Sale of company to |
![]() |
June 2017
|
![]() |
Company sale to |
![]() |
June 2017
|
![]() |
Has merged with Aspen Park Pharma to form |
![]() |
November 2016
|
![]() |
Company sale to |
![]() |
$100+ million
December 2015
|
![]() |
Sale to |
![]() |
$73 million
May 2022
|
![]() |
License of Ryaltris™ in the US to |
![]() |
February 2020
|
![]() |
Debt financing by |
![]() |
$57.5 million
February 2020
|
![]() |
Company sale to |
![]() |
$21.5 million
August 2019
|
![]() |
Sale of consumer products to |
![]() |
February 2018
|
![]() |
Merger with |
![]() |
$34.9 million
November 2017
|
![]() |
License of US rights to Posimir® to |
![]() |
$293 million
May 2017
|
![]() |
Sale of US dermatology business to |
![]() |
$13.6 million
May 2017
|
![]() |
Company sale to |
![]() |
$35.9 million
March 2017
|
![]() |
Acquired SLO Niacin® from |
![]() |
March 2017
|
![]() |
Licensed Nexafed® from |
![]() |
March 2017
|
![]() |
Licensing of Dalbavancin from |
![]() |
$13 million upfront
May 2016
|
![]() |
US license agreement for NATESTO® to |
![]() |
Up to $45.5 million
($8 million upfront) April 2016
|
![]() |
Royalty-backed acquisition financing for undisclosed spec pharma |
![]() |
$100 million
February 2016
|
![]() |
Sale to |
![]() |
June 2015
|
![]() |
Acquisition of Canadian rights to Estrace® from |
![]() |
$41 million
July 2014
|
![]() |
Sale to |
![]() |
19.9% of shares +
$12 million November 2013
|
![]() |
Sale for up to $106 million to |
![]() |
$12 million +
milestones January 2013
|
![]() |
Collaboration with |
![]() |
December 2012
|
![]() |
Sale of Amicar® rights to |
![]() |
August 2012
|
![]() |
Sale of Roxicodone® to |
![]() |
August 2012
|
![]() |
Sale of Zipsor® to |
![]() |
June 2012
|
![]() |
Sale to |
![]() |
$10 million +
milestones October 2011
|
![]() |
Sale of prenatal vitamin franchise |
![]() |
October 2011
|
![]() |
Sale of dermatology specialty pharma business to |
![]() |
December 2010
|
![]() |
Sale to |
![]() |
$100+ million
October 2010
|
![]() |
Sale of Crinone® & Prochieve® product lines and shares to |
![]() |
$92.5 million with
$47 million upfront July 2010
|
![]() |
Sale to |
![]() |
September 2008
|
![]() |
Sale to |
![]() |
April 2008
|